Cargando…

Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial

BACKGROUND: Treatment options for pretreated triple-negative breast cancer (TNBC) are limited. This study aimed to evaluate the efficacy and safety of apatinib, an antiangiogenic agent, in combination of etoposide for pretreated patients with advanced TNBC. METHODS: In this single-arm phase II trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Mengru, Lu, Hailing, Yan, Shi, Pang, Hui, Sun, Lichun, Li, Chunhong, Chen, Xuesong, Liu, Wei, Hu, Jing, Huang, Jian, Xing, Ying, Zhang, Ningzhi, Chen, Yingqi, He, Ting, Zhao, Danni, Sun, Yuanyuan, Zhao, Lin, Liu, Xiaomeng, Cai, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197030/ https://www.ncbi.nlm.nih.gov/pubmed/37208633 http://dx.doi.org/10.1186/s12885-023-10768-8

Ejemplares similares

Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
por: Xie, Lu, et al.
Publicado: (2021)

Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment
por: Chen, Siying, et al.
Publicado: (2021)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Weihua, et al.
Publicado: (2021)

Efficacy, safety and pharmacokinetics of apatinib plus etoposide versus apatinib alone for platinum-resistant recurrent ovarian cancer: protocol of a multicenter, open-label, randomized phase 2 trial
por: Hou, Zhiguo, et al.
Publicado: (2023)

Glutamine deprivation plus BPTES alters etoposide- and cisplatin-induced apoptosis in triple negative breast cancer cells
por: Chen, Lian, et al.
Publicado: (2016)

Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non‐small cell lung cancer: A meta‐analysis
por: Li, Zhe, et al.
Publicado: (2021)

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
por: Liu, Jieqiong, et al.
Publicado: (2022)

Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study
por: Wang, Chunjing, et al.
Publicado: (2023)

The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Chen, Lei, et al.
Publicado: (2021)

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma
por: Gao, Shen, et al.
Publicado: (2022)

Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study
por: Huang, Qi, et al.
Publicado: (2020)

A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer
por: Hu, Nanlin, et al.
Publicado: (2021)

Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer
por: Baur, M, et al.
Publicado: (2005)

Enabling factor for cancer hallmark acquisition: Small nucleolar RNA host gene 17
por: Zhang, Ningzhi, et al.
Publicado: (2022)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

The efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study
por: Li, Zhenyu, et al.
Publicado: (2023)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin
por: Chen, Xuesong, et al.
Publicado: (2016)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer
por: Wasamoto, Satoshi, et al.
Publicado: (2023)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)

ABCC3 as a marker for multidrug resistance in non-small cell lung cancer
por: Zhao, Yanbin, et al.
Publicado: (2013)

High Efficacy of Stem Cell Mobilization With Etoposide+Cytarabine Plus G-CSF in Patients With Multiple Myeloma
por: Zhu, Zhijuan, et al.
Publicado: (2022)

EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma
por: Keizer, H. Jan, et al.
Publicado: (1997)

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
por: van der Burg, M E L, et al.
Publicado: (2002)

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
por: Zhang, Longfeng, et al.
Publicado: (2020)

The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus
por: Zhang, Weihua, et al.
Publicado: (2022)

Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study
por: Wang, Yong, et al.
Publicado: (2019)

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
por: Zhang, Ruyan, et al.
Publicado: (2023)

Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
por: Shin, Wonkyo, et al.
Publicado: (2018)

Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
por: Li, Dou-Dou, et al.
Publicado: (2022)

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
por: Hu, Xichun, et al.
Publicado: (2014)

Efficacy of Oral Etoposide in Pretreated Metastatic Breast Cancer: A Multicenter Phase 2 Study
por: Yuan, Peng, et al.
Publicado: (2015)

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
por: de Jong, R. S., et al.
Publicado: (1997)

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
por: Ju, Shuguang, et al.
Publicado: (2022)

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
por: Gao, Guanghui, et al.
Publicado: (2022)

Efficacy of Oral Etoposide in Pretreated Metastatic Breast Cancer: A Multicenter Phase 2 Study: Erratum
Publicado: (2015)

The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases
por: Chen, Xuelian, et al.
Publicado: (2023)

Apatinib plus retinoic acid as maintenance for children with relapsed stage 4 high-risk neuroblastoma: Two case reports
por: Jin, Mei, et al.
Publicado: (2020)

Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7blqgs42m5djafjh4fn4et359d